What is Cardiosense?
Cardiosense is at the forefront of digital health innovation, developing a comprehensive platform that integrates medical-grade wearable devices with advanced clinical AI. This technology aims to identify early indicators of cardiac disease, enabling more personalized and effective patient treatments. The company's software is designed to aggregate and analyze physiological data, while its deep learning algorithms process raw waveforms for early disease detection. Cardiosense targets healthcare providers seeking to enhance cardiac care and patient monitoring with cutting-edge technology.
How much funding has Cardiosense raised?
Cardiosense has raised a total of $15.1M across 1 funding round:
Series A
$15.1M
Series A (2022): $15.1M with participation from Hatteras Venture Partners, OSF Ventures, Portal Innovations, Broadview Ventures, Laerdal Million Lives Fund, and UnityPoint Health Ventures
Key Investors in Cardiosense
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm specializing in transformative companies within biotech, MedTech, and HealthTech, providing capital and strategic support for innovative healthcare solutions.
OSF Ventures
OSF Ventures focuses on venture optimization, investing in companies that enhance patient outcomes and reduce healthcare system costs, operating as a division of OSF HealthCare.
Portal Innovations
Portal Innovations is a venture development engine and life sciences VC firm supporting early-stage biotech and medtech startups with capital, lab space, and strategic funding to accelerate breakthroughs.
What's next for Cardiosense?
The recent major strategic investment signals a pivotal growth phase for Cardiosense, likely enabling the company to scale its operations, further refine its AI-driven diagnostic tools, and expand its market reach. This capital infusion is expected to accelerate the development and deployment of its digital biomarker platform, solidifying its position in the competitive MedTech landscape. The company's focus on early cardiac disease detection and personalized treatment aligns with the growing demand for proactive and data-driven healthcare solutions.
See full Cardiosense company page
